ARCHIVES

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

This article is from The Cancer Letter archive.

Vol. 24 No. 5 | May 25, 2001

Download PDF Visit The Full Archive

Related Articles

Caterpillar In. Benefits Plan To Cover Entry On BMT trials

June 14, 1996

In Brief: Hohn Named President, CEO Of Roswell Park; Mendelsohn Honored; AACE Elects Officers

February 7, 1997

FDA Approves Lymphoseek For Imaging Lymph Nodes

March 29, 2013

Ohio State Breaks Ground For $1 Billion Expansion Of Medical Center, Cancer Hospital

June 18, 2010

FDA approves Irinotecan, Days After ODAC Meeting

June 21, 1996

In Brief: BMS Oncology Names New VP, Marketing; Hortobagyi Wins Freyer Medal; Prerez Honored

October 24, 1997